This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.
The investigators will evaluate clinical response rate, time to treatment Failure (TTF), overall survival (OS), and toxicity in cGVHD patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
Navy General Hospital
Beijing, Beijing Municipality, China
RECRUITINGOverall Response Rate (ORR)
Overall Response Rate (ORR) is defined as an Objective improvement at sixth month, and includes at least 1 of the following criteria: At least 50% reduction of body surface area involved; Reduction (at least 20%) of skin sclerosis, measured by Rodnan score Improvement\>1 point in functional pulmonary tests, evaluated by LFS score; \>50% steroid reduction (for at least 4 weeks)
Time frame: 12 months after date of start of Hydrogen
Response Rate in each domain (RRD)
Response rate in each domain was measured in subjects that had had initial involvement in that domain
Time frame: 12 months after date of start of Hydrogen
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.